Thursday, 20 November 2014 02:30 PM
Houston, TX / ACCESSWIRE / November 20, 2014 / American Liberty Petroleum Corp. continues to progress towards closing the previously announcing acquisition of Avant Diagnostics Inc., a medical technology company developing cutting edge medical diagnostic tests, including OvaDx(R), a Pre-Symptomatic Ovarian Cancer Screening Test. Both companies have signed an amendment to the Letter of Intent extending the closing date to no later than December 31st, 2014.
Steven M. Plumb, American Liberty Petroleum Corp.'s CFO commented on the progress towards closing, "We are now waiting on several key documents to be completed. With those completed, we will be able to close the acquisition and file the required SEC disclosure in a timely fashion."
About American Liberty Petroleum Corp.
American Liberty Petroleum Corp. ('OREO', http://americanlibertypetroleum.com/) is a fully reporting, development stage publicly traded company.
About Avant Diagnostics Inc.
Avant Diagnostics, Inc. ('Avant', http://avantdiagnostics.com/) is a medical technology company based on the completion of the human genome sequencing project. Avant is developing specialized tests that are cutting edge in medical diagnostic testing and the OvaDx(R) Pre-Symptomatic Ovarian Cancer Screening Test is a leading breakthrough in commercializing these tests.
Genetic research is increasingly focused on identifying the variations of the specific genes in the genome. These variations are what define individual characteristics, including disease states or a statistical propensity for disease. The implications are far-reaching and impact not only the research community, but also the individual patients and the medical providers. Diagnostic tests that detect diseases very early in their progression will provide options for earlier treatments that may improve the patient's quality of life and prognosis by delaying or preventing disease progression or even death. Medical providers will incur major cost savings by avoiding costly late stage disease treatments.
Safe Harbor
The statements in this press release that relate to American Liberty Petroleum Corp.'s expectations with regard to the future impact on American Liberty Petroleum Corp.'s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. American Liberty Petroleum Corp. undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in American Liberty Petroleum Corp.'s plans or expectations.
Investor Contact
Robert C. Rhodes
American Liberty Petroleum Corp.
[email protected]
Steven Scott or Gregg Linn
Avant Diagnostics, Inc.
[email protected]
SOURCE: American Liberty Petroleum Corp.